ES2189897T3 - Un derivado del factor viii recombinante humano. - Google Patents

Un derivado del factor viii recombinante humano.

Info

Publication number
ES2189897T3
ES2189897T3 ES97103685T ES97103685T ES2189897T3 ES 2189897 T3 ES2189897 T3 ES 2189897T3 ES 97103685 T ES97103685 T ES 97103685T ES 97103685 T ES97103685 T ES 97103685T ES 2189897 T3 ES2189897 T3 ES 2189897T3
Authority
ES
Spain
Prior art keywords
factor viii
human factor
derivative
dna segment
segment coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97103685T
Other languages
English (en)
Inventor
Anneli B Almstedt
Eva Maria Hellstrom
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2189897(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of ES2189897T3 publication Critical patent/ES2189897T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

UNA SECUENCIA DE ADN QUE CODIFICA UN DERIVADO DEL FACTOR VIII HUMANO RECOMBINANTE BIOLOGICAMENTE ACTIVO, QUE COMPRENDE UN PRIMER SEGMENTO DE ADN QUE CODIFICA LA CADENA DE 90 KDA DEL FACTOR VIII HUMANO Y UN SEGUNDO SEGMENTO DE ADN QUE CODIFICA LA CADENA DE 80 KDA DEL FACTOR VIII HUMANO, DICHOS SEGMENTOS ESTANDO INTERCONECTADOS POR UN SEGMENTO DE ADN DE ENLACE QUE CODIFICA UN PEPTIDO DE ENLACE DE 4 A ALREDEDOR DE 100 RESIDUOS DE AMINOACIDO DEL CAMPO B DEL FACTOR VIII HUMANO, AL MENOS 4 DE DICHOS RESIDUOS DE AMINOACIDO ORIGINADOS DEL TERMINAL C DE DICHO CAMPO; VECTOR DE EXPRESION RECOMBINANTE QUE COMPRENDE DICHA SECUENCIA DE ADN; CELULAS HUESPED DE ORIGEN ANIMAL TRANSFORMADAS CON DICHO VECTOR DE EXPRESION RECOMBINANTE; UN PROCEDIMIENTO PARA LA FABRICACION DE DERIVADO DE FACTOR VIII HUMANO RECOMBINANTE; Y DERIVADO DE FACTOR VIII HUMANO QUE CONTIENE LA CADENA PESADA Y LA CADENA LIGERA ENLAZADA MEDIANTE UNA UNION DE ION DE METAL.
ES97103685T 1989-12-15 1990-12-06 Un derivado del factor viii recombinante humano. Expired - Lifetime ES2189897T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Publications (1)

Publication Number Publication Date
ES2189897T3 true ES2189897T3 (es) 2003-07-16

Family

ID=20377785

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97103685T Expired - Lifetime ES2189897T3 (es) 1989-12-15 1990-12-06 Un derivado del factor viii recombinante humano.
ES91901327T Expired - Lifetime ES2119769T5 (es) 1989-12-15 1990-12-06 Derivado del factor viii humano recombinante.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES91901327T Expired - Lifetime ES2119769T5 (es) 1989-12-15 1990-12-06 Derivado del factor viii humano recombinante.

Country Status (21)

Country Link
EP (3) EP0786474B1 (es)
JP (1) JP2644084B2 (es)
AT (2) ATE170219T1 (es)
AU (1) AU645539B2 (es)
BR (1) BR9007921A (es)
CA (1) CA2071875C (es)
DE (3) DE69034040T2 (es)
DK (2) DK0506757T4 (es)
ES (2) ES2189897T3 (es)
FI (1) FI104260B1 (es)
HK (2) HK1019449A1 (es)
HU (1) HU211504A9 (es)
IE (1) IE904510A1 (es)
LU (1) LU90457I2 (es)
NL (1) NL990035I2 (es)
NO (1) NO309041B1 (es)
NZ (1) NZ236276A (es)
PT (1) PT96208B (es)
SE (1) SE465222C5 (es)
SG (1) SG66753A1 (es)
WO (1) WO1991009122A1 (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
SE468050C (sv) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP2002517180A (ja) 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE312176T1 (de) * 2000-03-22 2005-12-15 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
DK2287288T3 (da) 2002-07-09 2013-01-07 Baxter Int Medium frit for animalsk protein til dyrkning af celler
DK1596887T3 (da) 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
HUE033158T2 (en) 2003-09-30 2017-11-28 Univ Pennsylvania Adeno-associated virus (AAV) clusters, sequences, vectors containing them, and their use
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20180110192A (ko) 2004-11-12 2018-10-08 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP3603676A1 (en) 2005-04-07 2020-02-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1974014B1 (en) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptide-free cell culture media
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008102923A1 (en) 2007-02-23 2008-08-28 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
HUE036233T2 (hu) 2009-12-06 2018-06-28 Bioverativ Therapeutics Inc VIII-FC Faktor kimérás és hibrid polipeptidek, és ezek használati módszerei
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP5922095B2 (ja) 2010-03-29 2016-05-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 薬理学的に誘導される導入遺伝子アブレーション系
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
SG10201601110VA (en) 2011-02-17 2016-03-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
HUE046396T2 (hu) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc Kiméra faktor VIII polipeptidek és ezek alkalmazása
CN108465106B (zh) 2012-01-12 2022-05-27 普吉特海湾血液中心 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
KR102008190B1 (ko) 2012-02-15 2019-08-07 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
CN104427995A (zh) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 嵌合凝血因子
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
JP6603128B2 (ja) 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EP4223772A3 (en) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Optimized factor viii gene
ES2776195T3 (es) 2013-03-15 2020-07-29 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
MX2016005333A (es) 2013-10-22 2017-02-15 Dbv Tech Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015089077A2 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
ES2964658T3 (es) * 2014-07-25 2024-04-08 Csl Behring Gmbh Preparaciones mejoradas de Factor VIII para su uso en el tratamiento de la hemofilia A
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
BR112018015659A2 (pt) 2016-02-01 2018-12-26 Bioverativ Therapeutics Inc genes otimizados do fator viii
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
MA46967A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CN111918674A (zh) 2018-02-01 2020-11-10 比奥维拉迪维治疗股份有限公司 表达因子viii的慢病毒载体的用途
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
JP2021533753A (ja) 2018-08-09 2021-12-09 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density
EP4192515A2 (en) 2020-08-07 2023-06-14 Amicus Therapeutics, Inc. Vesicle targeting proteins and uses of same
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) * 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
AU656311B2 (en) * 1989-11-17 1995-02-02 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof

Also Published As

Publication number Publication date
PT96208B (pt) 1998-05-29
ATE232213T1 (de) 2003-02-15
HU211504A9 (en) 1995-11-28
ES2119769T5 (es) 2006-04-16
SE465222B (sv) 1991-08-12
CA2071875A1 (en) 1991-06-16
SE8904239L (sv) 1991-06-16
LU90457I2 (fr) 2001-04-13
SE8904239D0 (sv) 1989-12-15
DK0506757T4 (da) 2006-02-20
JPH05502161A (ja) 1993-04-22
DE19975066I2 (de) 2005-07-07
EP0786474A1 (en) 1997-07-30
BR9007921A (pt) 1992-11-10
ES2119769T3 (es) 1998-10-16
DE69032600T2 (de) 1999-01-07
AU7039391A (en) 1991-07-18
SG66753A1 (en) 2001-12-19
DE69032600T3 (de) 2006-07-20
EP0506757A1 (en) 1992-10-07
EP0506757B2 (en) 2005-10-26
DE69034040T2 (de) 2003-11-20
NL990035I1 (nl) 1999-12-01
EP1293513A3 (en) 2003-04-02
NZ236276A (en) 1993-03-26
ATE170219T1 (de) 1998-09-15
EP1293513A2 (en) 2003-03-19
FI922745A0 (fi) 1992-06-12
PT96208A (pt) 1991-09-30
WO1991009122A1 (en) 1991-06-27
NO309041B1 (no) 2000-12-04
FI104260B (fi) 1999-12-15
DE69034040D1 (de) 2003-03-13
NL990035I2 (nl) 2000-01-03
DK0786474T3 (da) 2003-03-03
NO922325L (no) 1992-08-11
AU645539B2 (en) 1994-01-20
HK1009290A1 (en) 1999-05-28
DE69032600D1 (de) 1998-10-01
IE904510A1 (en) 1991-07-17
CA2071875C (en) 2006-08-08
SE465222C5 (sv) 1998-02-10
EP0506757B1 (en) 1998-08-26
DK0506757T3 (da) 1999-05-25
JP2644084B2 (ja) 1997-08-25
NO922325D0 (no) 1992-06-12
HK1019449A1 (en) 2000-02-11
EP0786474B1 (en) 2003-02-05
FI104260B1 (fi) 1999-12-15

Similar Documents

Publication Publication Date Title
ES2189897T3 (es) Un derivado del factor viii recombinante humano.
SE9100799D0 (sv) Recombinant human factor viii derivatives
ATE209215T1 (de) Protegrine
NO971621L (no) Keratinocyttvekstfaktoranaloger
ATE198987T1 (de) Behandlung von tropikalischer spastischer paresis mit peptide t
DE69432427D1 (de) Tomate xyloglukan endotransglykosylase
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ATE96450T1 (de) Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken.